JRF Takeaways: BMAC is a biologic adjunct that may enhance outcomes following osteochondral allograft (OCA) transplantation. In this study, the addition of BMAC was associated with a reduced need for subsequent debridement and revision surgeries. Postoperative imaging revealed a greater incidence of small cystic changes in the BMAC group, with a trend toward reduced formation of larger cysts. Patients who received BMAC also demonstrated a trend toward improved KOOS JR scores at both 1- and 2-year follow-up. Further studies with larger sample sizes are warranted to further elicit these differences.
Click here for the complete abstract.
Authors: Adam B. Yanke, MD, PhD, Navya Dandu, MD, Blake M. Bodendorfer, MD, Nicholas A. Trasolini, MD, Mario Hevesi, MD, PhD, Tristan J. Elias, BA, Erik Haneberg, BS, Reem Y. Darwish, BS, Athan Zavras, MD, Brian Forsythe, MD, Brian J. Cole, MD, MBA
Published: The Journal of Arthroscopic and Related Surgery
Institution: Rush University Medical Center, Chicago, Illinois, Alleghany General Hospital, Pittsburgh, Pennsylvania, Wake Forest Baptist Health, Winston-Salem, North Carolina, and Mayo Clinic, Rochester, Minnesota.